Nowe strategie leczenia choroby Leśniowskiego-Crohna

Referencje

Honap S, Meade S, Spencer A, et al. Anogenital Crohn's Disease and Granulomatosis: A Systematic Review of Epidemiology, Clinical Manifestations, and Treatment [published correction appears in J Crohns Colitis. 2023 Jul 5;17(7):1175. doi: 10.1093/ecco-jcc/jjad044.]. J Crohns Colitis. 2022;16(5):822-834. doi:10.1093/ecco-jcc/jjab211

Bernett CN, Krishnamurthy K. Cutaneous Crohn Disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; January 9, 2023.

Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.

Baumgart DC, Sandborn WJ. Crohn's disease [published correction appears in Lancet. 2013 Jan 19;381(9862):204]. Lancet. 2012;380(9853):1590-1605. doi:10.1016/S0140-6736(12)60026-9

Horowitz JE, Warner N, Staples J, et al. Mutation spectrum of NOD2 reveals recessive inheritance as a main driver of Early Onset Crohn's Disease. Sci Rep. 2021;11(1):5595. Published 2021 Mar 10. doi:10.1038/s41598-021-84938-8

Kayali S, Fantasia S, Gaiani F, Cavallaro LG, de'Angelis GL, Laghi L. NOD2 and Crohn's Disease Clinical Practice: From Epidemiology to Diagnosis and Therapy, Rewired. Inflamm Bowel Dis. 2025;31(2):552-562. doi:10.1093/ibd/izae075

Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389(10080):1741-1755. doi:10.1016/S0140-6736(16)31711-1

Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146(6):1489-1499. doi:10.1053/j.gastro.2014.02.009

Sjödahl R, Järnerot G. Crohn's disease. Eur J Surg. 1998;164(12):883-886. doi:10.1080/110241598750005020

Yu YR, Rodriguez JR. Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017;26(6):349-355. doi:10.1053/j.sempedsurg.2017.10.003

Sendid B, Cornu M, Cordier C, Bouckaert J, Colombel JF, Poulain D. From ASCA breakthrough in Crohn's disease and Candida albicans research to thirty years of investigations about their meaning in human health. Autoimmun Rev. 2024;23(2):103486. doi:10.1016/j.autrev.2023.103486

Saibeni S, Folli C, de Franchis R, Borsi G, Vecchi M. Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases. Dig Liver Dis. 2003;35(12):862-868. doi:10.1016/j.dld.2003.07.001

Karczewski J, Swora-Cwynar E, Rzymski P, Poniedziałek B, Adamski Z. Selected biologic markers of inflammation and activity of Crohn's disease. Autoimmunity. 2015;48(5):318-327. doi:10.3109/08916934.2015.1016221

Yamamoto T. The clinical value of faecal calprotectin and lactoferrin measurement in postoperative Crohn's disease. United European Gastroenterol J. 2015;3(1):5-10. doi:10.1177/2050640614558106

Wright EK, Kamm MA, De Cruz P, et al. Comparison of Fecal Inflammatory Markers in Crohn's Disease. Inflamm Bowel Dis. 2016;22(5):1086-1094. doi:10.1097/MIB.0000000000000671

Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn's disease. Dis Mon. 2018;64(2):20-57. doi:10.1016/j.disamonth.2017.07.001

Magarotto A, Orlando S, Coletta M, Conte D, Fraquelli M, Caprioli F. Evolving roles of cross-sectional imaging in Crohn's disease. Dig Liver Dis. 2016;48(9):975-983. doi:10.1016/j.dld.2016.05.017

Tai FWD, Ellul P, Elosua A, et al. Panenteric capsule endoscopy identifies proximal small bowel disease guiding upstaging and treatment intensification in Crohn's disease: A European multicentre observational cohort study. United European Gastroenterol J. 2021;9(2):248-255. doi:10.1177/2050640620948664

Duan M, Guan B, Cao L, et al. Computed tomography enterography predicts surgical-free survival in symptomatic stricturing Crohn's disease. Abdom Radiol (NY). 2022;47(10):3414-3423. doi:10.1007/s00261-022-03588-0

Solem CA, Loftus EV Jr, Fletcher JG, et al. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008;68(2):255-266. doi:10.1016/j.gie.2008.02.017

Kim SH. Computed tomography enterography and magnetic resonance enterography in the diagnosis of Crohn's disease. Intest Res. 2015;13(1):27-38. doi:10.5217/ir.2015.13.1.27

Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583. doi:10.1053/j.gastro.2020.12.031

Cockburn E, Kamal S, Chan A, et al. Crohn's disease: an update. Clin Med (Lond). 2023;23(6):549-557. doi:10.7861/clinmed.2023-0493

De Cassan C, Fiorino G, Danese S. Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects?. Dig Dis. 2012;30(4):368-375. doi:10.1159/000338128

Vavricka SR, Schoepfer AM, Scharl M, Rogler G. Steroid use in Crohn's disease. Drugs. 2014;74(3):313-324. doi:10.1007/s40265-014-0183-y

Gionchetti P, Dignass A, Danese S, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations [published correction appears in J Crohns Colitis. 2023 Jan 27;17(1):149. doi: 10.1093/ecco-jcc/jjac104.]. J Crohns Colitis. 2017;11(2):135-149. doi:10.1093/ecco-jcc/jjw169

Pudipeddi A, Kariyawasam V, Haifer C, Baraty B, Paramsothy S, Leong RW. Safety of drugs used for the treatment of Crohn's disease. Expert Opin Drug Saf. 2019;18(5):357-367. doi:10.1080/14740338.2019.1612874

Shi HY, Ng SC. The state of the art on treatment of Crohn's disease. J Gastroenterol. 2018;53(9):989-998. doi:10.1007/s00535-018-1479-6

Cozijnsen MA, Samsom JN, de Ridder L. Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability. Paediatr Drugs. 2018;20(1):19-28. doi:10.1007/s40272-017-0266-9

Berns M, Hommes DW. Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future. Expert Opin Investig Drugs. 2016;25(2):129-143. doi:10.1517/13543784.2016.1126247

Danese S, Beaton A, Duncan EA, et al. Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn's disease. BMC Gastroenterol. 2023;23(1):451. Published 2023 Dec 20. doi:10.1186/s12876-023-03078-7

Sands BE, Chen J, Feagan BG, et al. Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. Gastroenterology. 2017;153(1):77-86.e6. doi:10.1053/j.gastro.2017.03.049

The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 2b QUASAR Study Results Through Week 12. Gastroenterol Hepatol (N Y). 2022;18(4 Suppl 1):12.

Liu J, Di B, Xu LL. Recent advances in the treatment of IBD: Targets, mechanisms and related therapies. Cytokine Growth Factor Rev. 2023;71-72:1-12. doi:10.1016/j.cytogfr.2023.07.001

Ma C, Jairath V, Vande Casteele N. Pharmacology, efficacy and safety of JAK inhibitors in Crohn's disease. Best Pract Res Clin Gastroenterol. 2019;38-39:101606. doi:10.1016/j.bpg.2019.03.002

Dell'Avalle C, D'Amico F, Gabbiadini R, et al. JAK inhibitors in crohn's disease: ready to go?. Expert Opin Investig Drugs. 2022;31(2):145-161. doi:10.1080/13543784.2022.2032639

Elhag DA, Kumar M, Saadaoui M, et al. Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. Int J Mol Sci. 2022;23(13):6966. Published 2022 Jun 23. doi:10.3390/ijms23136966

Verstockt B, Vetrano S, Salas A, et al. Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease [published correction appears in Nat Rev Gastroenterol Hepatol. 2022 Jun;19(6):410. doi: 10.1038/s41575-022-00597-8.]. Nat Rev Gastroenterol Hepatol. 2022;19(6):351-366. doi:10.1038/s41575-021-00574-7

Monteleone G, Stolfi C. Smad7 Antisense Oligonucleotide in Crohn's Disease: A Re-Evaluation and Explanation for the Discordant Results of Clinical Trials. Pharmaceutics. 2022;15(1):95. Published 2022 Dec 28. doi:10.3390/pharmaceutics15010095

Ardizzone S, Bevivino G, Monteleone G. Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn's disease. Therap Adv Gastroenterol. 2016;9(4):527-532. doi:10.1177/1756283X16636781

Sobocińska AA, Czarnecka AM, Szczylik C. Mechanisms of angiogenesis in neoplasia. Postepy Hig Med Dosw (Online). 2016;70(0):1166-1181. Published 2016 Dec 8

Picchianti-Diamanti A, Spinelli FR, Rosado MM, Conti F, Laganà B. Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases. Int J Mol Sci. 2021;22(5):2638. Published 2021 Mar 5. doi:10.3390/ijms22052638

Huang Z, Ducharme Y, Macdonald D, Robichaud A. The next generation of PDE4 inhibitors. Curr Opin Chem Biol. 2001;5(4):432-438. doi:10.1016/s1367-5931(00)00224-6

Meima-van Praag EM, Buskens CJ, Hompes R, Bemelman WA. Surgical management of Crohn's disease: a state of the art review. Int J Colorectal Dis. 2021;36(6):1133-1145. doi:10.1007/s00384-021-03857-2

Ullrich SJ, Frischer JS. Surgical management of complicated Crohn's disease. Semin Pediatr Surg. 2024;33(2):151399.doi:10.1016/j.sempedsurg.2024.151399

Sleiman J, El Ouali S, Qazi T, et al. Prevention and Treatment of Stricturing Crohn's Disease - Perspectives and Challenges. Expert Rev Gastroenterol Hepatol. 2021;15(4):401-411. doi:10.1080/17474124.2021.1854732

Meima-van Praag EM, Buskens CJ, Hompes R, Bemelman WA. Surgical management of Crohn's disease: a state of the art review. Int J Colorectal Dis. 2021;36(6):1133-1145. doi:10.1007/s00384-021-03857-2

Wasmann KA; IBD study group Amsterdam UMC, location AMC . Complications While Waiting for IBD Surgery-Short Report. J Crohns Colitis. 2020;14(2):277-280. doi:10.1093/ecco-jcc/jjz143

Carvello M, Lightner A, Yamamoto T, Kotze PG, Spinelli A. Mesenchymal Stem Cells for Perianal Crohn's Disease. Cells. 2019;8(7):764. Published 2019 Jul 23. doi:10.3390/cells8070764

Mohammadi TC, Jazi K, Bolouriyan A, Soleymanitabar A. Stem cells in treatment of crohn's disease: Recent advances and future directions. Transpl Immunol. 2023;80:101903. doi:10.1016/j.trim.2023.101903